JP2015535215A - 細胞結合剤細胞毒性剤コンジュゲートから不純物を除去するためのイオン交換膜の使用 - Google Patents

細胞結合剤細胞毒性剤コンジュゲートから不純物を除去するためのイオン交換膜の使用 Download PDF

Info

Publication number
JP2015535215A
JP2015535215A JP2015535827A JP2015535827A JP2015535215A JP 2015535215 A JP2015535215 A JP 2015535215A JP 2015535827 A JP2015535827 A JP 2015535827A JP 2015535827 A JP2015535827 A JP 2015535827A JP 2015535215 A JP2015535215 A JP 2015535215A
Authority
JP
Japan
Prior art keywords
mixture
cell binding
binding agent
cytotoxic agent
agent
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Pending
Application number
JP2015535827A
Other languages
English (en)
Japanese (ja)
Inventor
リ、シンファン
シェン、ウェンジー
Original Assignee
イムノゲン インコーポレーティッド
イムノゲン インコーポレーティッド
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by イムノゲン インコーポレーティッド, イムノゲン インコーポレーティッド filed Critical イムノゲン インコーポレーティッド
Publication of JP2015535215A publication Critical patent/JP2015535215A/ja
Pending legal-status Critical Current

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies
    • C07K16/06—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies from serum
    • C07K16/065—Purification, fragmentation
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/50—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates
    • A61K47/51—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent
    • A61K47/68—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent the modifying agent being an antibody, an immunoglobulin or a fragment thereof, e.g. an Fc-fragment
    • A61K47/6801—Drug-antibody or immunoglobulin conjugates defined by the pharmacologically or therapeutically active agent
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/50—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates
    • A61K47/51—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent
    • A61K47/68—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent the modifying agent being an antibody, an immunoglobulin or a fragment thereof, e.g. an Fc-fragment
    • A61K47/6835—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent the modifying agent being an antibody, an immunoglobulin or a fragment thereof, e.g. an Fc-fragment the modifying agent being an antibody or an immunoglobulin bearing at least one antigen-binding site
    • A61K47/6849—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent the modifying agent being an antibody, an immunoglobulin or a fragment thereof, e.g. an Fc-fragment the modifying agent being an antibody or an immunoglobulin bearing at least one antigen-binding site the antibody targeting a receptor, a cell surface antigen or a cell surface determinant
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies
    • C07K16/18—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans
    • C07K16/28—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants
    • C07K16/2863—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants against receptors for growth factors, growth regulators
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies
    • C07K16/18—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans
    • C07K16/28—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants
    • C07K16/2878—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants against the NGF-receptor/TNF-receptor superfamily, e.g. CD27, CD30, CD40, CD95
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies
    • C07K16/18—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans
    • C07K16/28—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants
    • C07K16/2896—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants against molecules with a "CD"-designation, not provided for elsewhere
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies
    • C07K16/18—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans
    • C07K16/32—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans against translation products of oncogenes
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies
    • C07K16/40—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against enzymes
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/20—Immunoglobulins specific features characterized by taxonomic origin
    • C07K2317/24—Immunoglobulins specific features characterized by taxonomic origin containing regions, domains or residues from different species, e.g. chimeric, humanized or veneered

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Immunology (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • General Health & Medical Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Biochemistry (AREA)
  • Biophysics (AREA)
  • Genetics & Genomics (AREA)
  • Molecular Biology (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Epidemiology (AREA)
  • Animal Behavior & Ethology (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Cell Biology (AREA)
  • Oncology (AREA)
  • Peptides Or Proteins (AREA)
  • Medicinal Preparation (AREA)
  • Medicines Containing Material From Animals Or Micro-Organisms (AREA)
  • Treatment Of Liquids With Adsorbents In General (AREA)
JP2015535827A 2012-10-04 2013-10-04 細胞結合剤細胞毒性剤コンジュゲートから不純物を除去するためのイオン交換膜の使用 Pending JP2015535215A (ja)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
US201261709871P 2012-10-04 2012-10-04
US61/709,871 2012-10-04
PCT/US2013/063503 WO2014055893A1 (en) 2012-10-04 2013-10-04 Use of an ion exchange membrane to remove impurities from cell-binding agent cytotoxic agent conjugates

Publications (1)

Publication Number Publication Date
JP2015535215A true JP2015535215A (ja) 2015-12-10

Family

ID=50435480

Family Applications (1)

Application Number Title Priority Date Filing Date
JP2015535827A Pending JP2015535215A (ja) 2012-10-04 2013-10-04 細胞結合剤細胞毒性剤コンジュゲートから不純物を除去するためのイオン交換膜の使用

Country Status (13)

Country Link
US (1) US20150307596A1 (cg-RX-API-DMAC7.html)
EP (1) EP2903450A4 (cg-RX-API-DMAC7.html)
JP (1) JP2015535215A (cg-RX-API-DMAC7.html)
CN (1) CN105208876A (cg-RX-API-DMAC7.html)
AU (1) AU2013326897A1 (cg-RX-API-DMAC7.html)
CA (1) CA2886996A1 (cg-RX-API-DMAC7.html)
HK (1) HK1213148A1 (cg-RX-API-DMAC7.html)
IL (1) IL238111A0 (cg-RX-API-DMAC7.html)
IN (1) IN2015DN03203A (cg-RX-API-DMAC7.html)
MX (1) MX2015004258A (cg-RX-API-DMAC7.html)
RU (1) RU2015116883A (cg-RX-API-DMAC7.html)
SG (1) SG11201502430QA (cg-RX-API-DMAC7.html)
WO (1) WO2014055893A1 (cg-RX-API-DMAC7.html)

Families Citing this family (8)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US7811572B2 (en) 2005-08-24 2010-10-12 Immunogen, Inc. Process for preparing purified drug conjugates
JP5784592B2 (ja) 2009-06-03 2015-09-24 イミュノジェン・インコーポレーテッド 抱合方法
EA033468B1 (ru) 2011-03-29 2019-10-31 Immunogen Inc Способы получения конъюгата "антитело-майтансиноид"
EP2904089A4 (en) * 2012-10-04 2016-05-25 Immunogen Inc USE OF A PVDF MEMBRANE FOR PURIFYING CELL BINDING AGENT-CYTOTOXIC AGENT CONJUGATES
GB201616758D0 (en) * 2016-10-03 2016-11-16 Ge Healthcare Bio Sciences Ab Novel chromatography media
CN108549763B (zh) * 2018-04-09 2021-06-01 电子科技大学 一种用于离子推进器数值模拟的电荷交换碰撞mcc方法
CN118290514B (zh) * 2024-06-05 2025-04-04 东曜药业有限公司 基于阴离子膜的抗体偶联药物的纯化方法及抗体偶联药物
CN118290513B (zh) * 2024-06-05 2025-03-14 东曜药业有限公司 一种去除抗体偶联药物中游离小分子的阴离子柱层析方法及抗体偶联药物

Family Cites Families (7)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
NZ533657A (en) * 2002-01-03 2008-01-31 Smithkline Beecham Corp Methods for the preparation of immunoconjugates, in particular maytansinoids conjugated to a monoclonal antibody
US20090068178A1 (en) * 2002-05-08 2009-03-12 Genentech, Inc. Compositions and Methods for the Treatment of Tumor of Hematopoietic Origin
US20110166319A1 (en) * 2005-02-11 2011-07-07 Immunogen, Inc. Process for preparing purified drug conjugates
AU2006213662B2 (en) * 2005-02-11 2010-08-05 Immunogen, Inc. Process for preparing stable drug conjugates
US7811572B2 (en) * 2005-08-24 2010-10-12 Immunogen, Inc. Process for preparing purified drug conjugates
JP5784592B2 (ja) * 2009-06-03 2015-09-24 イミュノジェン・インコーポレーテッド 抱合方法
EA033468B1 (ru) * 2011-03-29 2019-10-31 Immunogen Inc Способы получения конъюгата "антитело-майтансиноид"

Also Published As

Publication number Publication date
CN105208876A (zh) 2015-12-30
WO2014055893A1 (en) 2014-04-10
RU2015116883A (ru) 2016-11-27
CA2886996A1 (en) 2014-04-10
EP2903450A1 (en) 2015-08-12
AU2013326897A1 (en) 2015-05-07
IN2015DN03203A (cg-RX-API-DMAC7.html) 2015-10-02
SG11201502430QA (en) 2015-04-29
MX2015004258A (es) 2015-09-25
HK1213148A1 (zh) 2016-06-30
IL238111A0 (en) 2015-05-31
US20150307596A1 (en) 2015-10-29
EP2903450A4 (en) 2016-05-11

Similar Documents

Publication Publication Date Title
US11744900B2 (en) Preparation of maytansinoid antibody conjugates by a one-step process
JP6345181B2 (ja) 細胞結合剤細胞毒性剤コンジュゲートを精製するためのpvdf膜の使用
US20160101191A1 (en) Process for manufacturing conjugates of improved homogeneity
WO2012135522A2 (en) Process for manufacturing conjugates of improved homogeneity
US20150306242A1 (en) Process for preparing stable antibody maytansinoid conjugates
US20160045616A1 (en) Process for preparing purified drug conjugates
EP2903450A1 (en) Use of an ion exchange membrane to remove impurities from cell-binding agent cytotoxic agent conjugates
NZ616509B2 (en) Preparation of maytansinoid antibody conjugates by a one-step process
NZ616516B2 (en) Process for manufacturing conjugates of improved homogeneity
NZ712414B2 (en) Preparation of antibody maytansinoid conjugates

Legal Events

Date Code Title Description
A521 Request for written amendment filed

Free format text: JAPANESE INTERMEDIATE CODE: A821

Effective date: 20150619

RD01 Notification of change of attorney

Free format text: JAPANESE INTERMEDIATE CODE: A7426

Effective date: 20150619